139 related articles for article (PubMed ID: 35704853)
1. Structure-Based Discovery of a Series of NSD2-PWWP1 Inhibitors.
Li N; Yang H; Liu K; Zhou L; Huang Y; Cao D; Li Y; Sun Y; Yu A; Du Z; Yu F; Zhang Y; Wang B; Geng M; Li J; Xiong B; Xu S; Huang X; Liu T
J Med Chem; 2022 Jul; 65(13):9459-9477. PubMed ID: 35704853
[TBL] [Abstract][Full Text] [Related]
2. A chemical probe targeting the PWWP domain alters NSD2 nucleolar localization.
Dilworth D; Hanley RP; Ferreira de Freitas R; Allali-Hassani A; Zhou M; Mehta N; Marunde MR; Ackloo S; Carvalho Machado RA; Khalili Yazdi A; Owens DDG; Vu V; Nie DY; Alqazzaz M; Marcon E; Li F; Chau I; Bolotokova A; Qin S; Lei M; Liu Y; Szewczyk MM; Dong A; Kazemzadeh S; Abramyan T; Popova IK; Hall NW; Meiners MJ; Cheek MA; Gibson E; Kireev D; Greenblatt JF; Keogh MC; Min J; Brown PJ; Vedadi M; Arrowsmith CH; Barsyte-Lovejoy D; James LI; Schapira M
Nat Chem Biol; 2022 Jan; 18(1):56-63. PubMed ID: 34782742
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in nuclear receptor-binding SET domain 2 (NSD2) inhibitors: An update and perspectives.
Zhang L; Zha X
Eur J Med Chem; 2023 Mar; 250():115232. PubMed ID: 36863225
[TBL] [Abstract][Full Text] [Related]
4. Discovery of Small-Molecule Antagonists of the PWWP Domain of NSD2.
Ferreira de Freitas R; Liu Y; Szewczyk MM; Mehta N; Li F; McLeod D; Zepeda-Velázquez C; Dilworth D; Hanley RP; Gibson E; Brown PJ; Al-Awar R; James LI; Arrowsmith CH; Barsyte-Lovejoy D; Min J; Vedadi M; Schapira M; Allali-Hassani A
J Med Chem; 2021 Feb; 64(3):1584-1592. PubMed ID: 33522809
[TBL] [Abstract][Full Text] [Related]
5. Histone and DNA binding ability studies of the NSD subfamily of PWWP domains.
Zhang M; Yang Y; Zhou M; Dong A; Yan X; Loppnau P; Min J; Liu Y
Biochem Biophys Res Commun; 2021 Sep; 569():199-206. PubMed ID: 34271259
[TBL] [Abstract][Full Text] [Related]
6. Discovery of NSD2-Degraders from Novel and Selective DEL Hits.
LegaardAndersson J; Christensen J; Kleine-Kohlbrecher D; Vacher Comet I; Fullerton Støier J; Antoku Y; Poljak V; Moretti L; Dolberg J; Jacso T; Jensby Nielsen S; Nørregaard-Madsen M; Franch T; Helin K; Cloos PAC
Chembiochem; 2023 Dec; 24(24):e202300515. PubMed ID: 37807669
[TBL] [Abstract][Full Text] [Related]
7. Identification of Novel Potent NSD2-PWWP1 Ligands Using Structure-Based Design and Computational Approaches.
Carlino L; Astles PC; Ackroyd B; Ahmed A; Chan C; Collie GW; Dale IL; O'Donovan DH; Fawcett C; di Fruscia P; Gohlke A; Guo X; Hao-Ru Hsu J; Kaplan B; Milbradt AG; Northall S; Petrović D; Rivers EL; Underwood E; Webb A
J Med Chem; 2024 May; ():. PubMed ID: 38748070
[TBL] [Abstract][Full Text] [Related]
8. A PWWP Domain of Histone-Lysine N-Methyltransferase NSD2 Binds to Dimethylated Lys-36 of Histone H3 and Regulates NSD2 Function at Chromatin.
Sankaran SM; Wilkinson AW; Elias JE; Gozani O
J Biol Chem; 2016 Apr; 291(16):8465-74. PubMed ID: 26912663
[TBL] [Abstract][Full Text] [Related]
9. High-throughput screening with nucleosome substrate identifies small-molecule inhibitors of the human histone lysine methyltransferase NSD2.
Coussens NP; Kales SC; Henderson MJ; Lee OW; Horiuchi KY; Wang Y; Chen Q; Kuznetsova E; Wu J; Chakka S; Cheff DM; Cheng KC; Shinn P; Brimacombe KR; Shen M; Simeonov A; Lal-Nag M; Ma H; Jadhav A; Hall MD
J Biol Chem; 2018 Aug; 293(35):13750-13765. PubMed ID: 29945974
[TBL] [Abstract][Full Text] [Related]
10. Discovery of LLC0424 as a Potent and Selective
Liu L; Parolia A; Liu Y; Hou C; He T; Qiao Y; Eyunni S; Luo J; Li C; Wang Y; Zhou F; Huang W; Ren X; Wang Z; Chinnaiyan AM; Ding K
J Med Chem; 2024 May; 67(9):6938-6951. PubMed ID: 38687638
[TBL] [Abstract][Full Text] [Related]
11. Fragment-based discovery of a chemical probe for the PWWP1 domain of NSD3.
Böttcher J; Dilworth D; Reiser U; Neumüller RA; Schleicher M; Petronczki M; Zeeb M; Mischerikow N; Allali-Hassani A; Szewczyk MM; Li F; Kennedy S; Vedadi M; Barsyte-Lovejoy D; Brown PJ; Huber KVM; Rogers CM; Wells CI; Fedorov O; Rumpel K; Zoephel A; Mayer M; Wunberg T; Böse D; Zahn S; Arnhof H; Berger H; Reiser C; Hörmann A; Krammer T; Corcokovic M; Sharps B; Winkler S; Häring D; Cockcroft XL; Fuchs JE; Müllauer B; Weiss-Puxbaum A; Gerstberger T; Boehmelt G; Vakoc CR; Arrowsmith CH; Pearson M; McConnell DB
Nat Chem Biol; 2019 Aug; 15(8):822-829. PubMed ID: 31285596
[TBL] [Abstract][Full Text] [Related]
12. 5-Aminonaphthalene derivatives as selective nonnucleoside nuclear receptor binding SET domain-protein 2 (NSD2) inhibitors for the treatment of multiple myeloma.
Wang S; Yang H; Su M; Lian F; Cong Z; Wei R; Zhou Y; Li X; Zheng X; Li C; Fu X; Han X; Shi Q; Li C; Zhang N; Geng M; Liu H; Li J; Huang X; Wang J
Eur J Med Chem; 2021 Oct; 222():113592. PubMed ID: 34147909
[TBL] [Abstract][Full Text] [Related]
13. In vitro histone lysine methylation by NSD1, NSD2/MMSET/WHSC1 and NSD3/WHSC1L.
Morishita M; Mevius D; di Luccio E
BMC Struct Biol; 2014 Dec; 14():25. PubMed ID: 25494638
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a First-in-Class Degrader for Nuclear Receptor Binding SET Domain Protein 2 (NSD2) and Ikaros/Aiolos.
Meng F; Xu C; Park KS; Kaniskan HÜ; Wang GG; Jin J
J Med Chem; 2022 Aug; 65(15):10611-10625. PubMed ID: 35895319
[TBL] [Abstract][Full Text] [Related]
15. Drug Discovery Targeting Nuclear Receptor Binding SET Domain Protein 2 (NSD2).
Ma Z; Bolinger AA; Chen H; Zhou J
J Med Chem; 2023 Aug; 66(16):10991-11026. PubMed ID: 37578463
[TBL] [Abstract][Full Text] [Related]
16. Defining the NSD2 interactome: PARP1 PARylation reduces NSD2 histone methyltransferase activity and impedes chromatin binding.
Huang X; LeDuc RD; Fornelli L; Schunter AJ; Bennett RL; Kelleher NL; Licht JD
J Biol Chem; 2019 Aug; 294(33):12459-12471. PubMed ID: 31248990
[TBL] [Abstract][Full Text] [Related]
17. Structural basis of the regulation of the normal and oncogenic methylation of nucleosomal histone H3 Lys36 by NSD2.
Sato K; Kumar A; Hamada K; Okada C; Oguni A; Machiyama A; Sakuraba S; Nishizawa T; Nureki O; Kono H; Ogata K; Sengoku T
Nat Commun; 2021 Nov; 12(1):6605. PubMed ID: 34782608
[TBL] [Abstract][Full Text] [Related]
18. The catalytic domain of the histone methyltransferase NSD2/MMSET is required for the generation of B1 cells in mice.
Dobenecker MW; Marcello J; Becker A; Rudensky E; Bhanu NV; Carrol T; Garcia BA; Prinjha R; Yurchenko V; Tarakhovsky A
FEBS Lett; 2020 Oct; 594(20):3324-3337. PubMed ID: 32862441
[TBL] [Abstract][Full Text] [Related]
19. NSD2 as a Promising Target in Hematological Disorders.
Azagra A; Cobaleda C
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232375
[TBL] [Abstract][Full Text] [Related]
20. Reprogramming metabolism by histone methyltransferase NSD2 drives endocrine resistance via coordinated activation of pentose phosphate pathway enzymes.
Wang J; Duan Z; Nugent Z; Zou JX; Borowsky AD; Zhang Y; Tepper CG; Li JJ; Fiehn O; Xu J; Kung HJ; Murphy LC; Chen HW
Cancer Lett; 2016 Aug; 378(2):69-79. PubMed ID: 27164560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
